| __timestamp | BioMarin Pharmaceutical Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 5078000000 |
| Thursday, January 1, 2015 | 402271000 | 4717000000 |
| Friday, January 1, 2016 | 476593000 | 5096000000 |
| Sunday, January 1, 2017 | 554336000 | 4986000000 |
| Monday, January 1, 2018 | 604353000 | 4214000000 |
| Tuesday, January 1, 2019 | 680924000 | 3806000000 |
| Wednesday, January 1, 2020 | 737669000 | 3671000000 |
| Friday, January 1, 2021 | 759375000 | 3528000000 |
| Saturday, January 1, 2022 | 854009000 | 3445000000 |
| Sunday, January 1, 2023 | 937300000 | 3498000000 |
| Monday, January 1, 2024 | 1009025000 | 3702000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and BioMarin Pharmaceutical Inc. over the past decade.
From 2014 to 2023, BioMarin's SG&A expenses have shown a consistent upward trend, increasing by approximately 210%. This growth reflects the company's expanding operations and strategic investments in marketing and administration. In contrast, Teva's SG&A expenses have decreased by about 31% during the same period, indicating a strategic shift towards cost optimization and efficiency.
BioMarin's rising expenses suggest a focus on growth and market penetration, while Teva's cost-cutting measures highlight a strategy of consolidation and efficiency. These trends offer valuable insights into the strategic priorities of these pharmaceutical giants, providing a window into their future trajectories.
Merck & Co., Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Pharming Group N.V.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation